Measuring Biologic Resilience in Older Cancer Survivors - PubMed (original) (raw)

Review

. 2021 Jul 1;39(19):2079-2089.

doi: 10.1200/JCO.21.00245. Epub 2021 May 27.

Affiliations

Review

Measuring Biologic Resilience in Older Cancer Survivors

Mina S Sedrak et al. J Clin Oncol. 2021.

No abstract available

Mina S. SedrakResearch Funding: Novartis, Seattle Genetics, Lilly, PfizerNo other potential conflicts of interest were reported.

FIG 1.

Longitudinal response to cancer therapy is dynamic and variable.

FIG 2.

Conceptual framework of resilience and cancer therapy.

1. Bluethmann SM, Mariotto AB, Rowland JH.Anticipating the “Silver Tsunami”: Prevalence trajectories and comorbidity burden among older cancer survivors in the United States Cancer Epidemiol Biomarkers Prev 251029–10362016 -PMC -PubMed
1. Jacobsen PB, Rowland JH, Paskett ED, et al. Identification of key gaps in cancer survivorship research: Findings from the American Society of Clinical Oncology survey J Oncol Pract 12190–1932016 -PubMed
1. Hodes RJ, Sierra F, Austad SN, et al. Disease drivers of aging Ann N Y Acad Sci 138645–682016 -PMC -PubMed
1. Dowling EC, Chawla N, Forsythe LP, et al. Lost productivity and burden of illness in cancer survivors with and without other chronic conditions Cancer 1193393–34012013 -PMC -PubMed
1. Keating NL, Nørredam M, Landrum MB, et al. Physical and mental health status of older long-term cancer survivors J Am Geriatr Soc 532145–21522005 -PubMed